Search hospitals > Arizona > Phoenix
Cancer Center at Saint Joseph's
Claim this profilePhoenix, Arizona 85004
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Prostate Cancer
Conducts research for Tumors
131 reported clinical trials
4 medical researchers
Summary
Cancer Center at Saint Joseph's is a medical facility located in Phoenix, Arizona. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Prostate Cancer, Tumors and other specialties. Cancer Center at Saint Joseph's is involved with conducting 131 clinical trials across 290 conditions. There are 4 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Jue Wang, and John H. Farley.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderHER2 positive
HER2 negative
ER positive
Top PIs
Richard L. DemingMercy Medical Center - Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
172 reported clinical trials
239 drugs studied
Shahzad SiddiquePenrose-Saint Francis Healthcare4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
111 reported clinical trials
176 drugs studied
Jue WangCancer Center at Saint Joseph's7 years of reported clinical research
Studies Cancer
Studies Tumors
4 reported clinical trials
23 drugs studied
John H. FarleyUniversity of Arizona Cancer Center at Saint Joseph's4 years of reported clinical research
Studies Ovarian Cancer
Studies Peritoneal Serous Adenocarcinoma
2 reported clinical trials
7 drugs studied
Clinical Trials running at Cancer Center at Saint Joseph's
Breast Cancer
Bladder Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Multiple Myeloma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Center at Saint Joseph's?
Cancer Center at Saint Joseph's is a medical facility located in Phoenix, Arizona. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Prostate Cancer, Tumors and other specialties. Cancer Center at Saint Joseph's is involved with conducting 131 clinical trials across 290 conditions. There are 4 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, Jue Wang, and John H. Farley.